ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cambrex Acquires Biocatalyst Firm IEP

by Rick Mullin
March 29, 2010 | APPEARED IN VOLUME 88, ISSUE 13

Cambrex has acquired IEP, a Wiesbaden, Germany-based firm that specializes in developing biocatalytic processes and making enzymes for drug companies. “In combination with our existing chiral chemistry business, the acquisition of IEP will result in Cambrex’ being able to offer a broad biocatalysis platform to the pharmaceutical industry,” says Cambrex CEO Steven M. Klosk. Biocatalysis is of growing interest to fine chemicals companies. In 2004, for example, IEP contributed biocatalysis expertise to a chiral chemistry consortium formed by Almac Sciences.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment